Brief: Aeglea Bio Therapeutics Inc Received Notice Of Delisting From Nasdaq

Spyre Therapeutics

25/09/2023 21:12

Sept 25 (Reuters) - Aeglea Bio Therapeutics Inc
 AGLE.O :
    * AEGLEA BIO THERAPEUTICS INC- IN APRIL 2023, PARAGON
THERAPEUTICS
AND WUXI BIOLOGICS (HONG KONG) LIMITED ENTERED BIOLOGICS MASTER
SERVICES AGREEMENT
    * AEGLEA BIO THERAPEUTICS INC- WUXI BIOLOGICS MSA WAS
NOVATED TO
AEGLEA BIOTHERAPEUTICS BY PARAGON ON SEPTEMBER 19 PURSUANT TO
NOVATION AGREEMENT
    * AEGLEA BIO THERAPEUTICS INC- WUXI BIOLOGICS MSA GOVERNS
CERTAIN
DEVELOPMENT ACTIVITIES AND GMP MANUFACTURING AND TESTING FOR
CO'S SPY001 PROGRAM
    * AEGLEA BIO THERAPEUTICS INC - ON SEPT 22, CO RECEIVED
NOTICE OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
    * AEGLEA BIO THERAPEUTICS - UNDER WUXI BIOLOGICS MSA, CO TO
PAY
WUXI BIOLOGICS SERVICE FEE, ALL NON-CANCELLABLE OBLIGATIONS


Further company coverage:  AGLE.O 

 ((Reuters.Briefs@thomsonreuters.com;))